A study of patients with DLBCL in the Middle East and Africa
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at patients with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. It aims to understand how the disease is treated, what treatments are available, and how patients access newer therapies. You simply continue your regular care and the study team collects information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- You are either about to start your first treatment for DLBCL, or you have already received at least one treatment that didn't work.
- You do not have any other active cancer.
- You are not currently taking part in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.